Published in Eur J Nucl Med Mol Imaging on June 20, 2008
Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol (2009) 4.06
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev (2010) 2.70
Multimodality imaging probes: design and challenges. Chem Rev (2010) 2.61
Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol (2009) 2.02
In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano (2012) 1.53
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev (2011) 1.36
Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. Trends Mol Med (2010) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis (2010) 1.26
Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent. Transl Oncol (2010) 1.26
In vivo tumor-targeted fluorescence imaging using near-infrared non-cadmium quantum dots. Bioconjug Chem (2010) 1.24
Optical imaging-guided cancer therapy with fluorescent nanoparticles. J R Soc Interface (2009) 1.22
Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med (2010) 1.21
In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene. Biomaterials (2012) 1.07
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol Med (2012) 1.07
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
Radiolabeled nanoparticles for multimodality tumor imaging. Theranostics (2014) 1.01
Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. PLoS One (2009) 1.00
Cancer-targeted optical imaging with fluorescent zinc oxide nanowires. Nano Lett (2011) 1.00
A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem (2010) 1.00
Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep (2014) 1.00
Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials. Small (2014) 0.98
Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol (2010) 0.97
Positron emission tomography imaging using radiolabeled inorganic nanomaterials. Acc Chem Res (2015) 0.96
Molecular imaging with nucleic acid aptamers. Curr Med Chem (2011) 0.96
Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials (2011) 0.96
Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res (2012) 0.96
In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol Pharm (2014) 0.93
Near-infrared quantum dots as optical probes for tumor imaging. Curr Top Med Chem (2010) 0.92
Targeted nanotechnology for cancer imaging. Adv Drug Deliv Rev (2014) 0.91
Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur J Nucl Med Mol Imaging (2009) 0.89
Molecular imaging of cell-based cancer immunotherapy. Mol Biosyst (2011) 0.88
In a "nutshell": intrinsically radio-labeled quantum dots. Am J Nucl Med Mol Imaging (2012) 0.88
Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development. Biomed Res Int (2014) 0.88
Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals (2012) 0.87
Nanoparticles for Improving Cancer Diagnosis. Mater Sci Eng R Rep (2013) 0.87
Fluorescence imaging of vascular endothelial growth factor in tumors for mice embedded in a turbid medium. J Biomed Opt (2010) 0.86
Heptamethine cyanine based (64)Cu-PET probe PC-1001 for cancer imaging: synthesis and in vivo evaluation. Nucl Med Biol (2013) 0.85
Quantum dots for multimodal molecular imaging of angiogenesis. Angiogenesis (2010) 0.84
Quantum dot-based nanoprobes for in vivo targeted imaging. Curr Mol Med (2013) 0.83
Inorganic nanomaterials for tumor angiogenesis imaging. Eur J Nucl Med Mol Imaging (2010) 0.83
Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging (2010) 0.83
Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics. Adv Drug Deliv Rev (2016) 0.81
Triple-Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours In Vivo. Theranostics (2016) 0.81
Pharmacokinetic issues of imaging with nanoparticles: focusing on carbon nanotubes and quantum dots. Mol Imaging Biol (2013) 0.81
Optical imaging probes in oncology. Oncotarget (2016) 0.81
VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl Mater Interfaces (2014) 0.81
Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo. ACS Nano (2010) 0.80
VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo. Biomaterials (2014) 0.79
In vitro and in vivo imaging of prostate cancer angiogenesis using anti-vascular endothelial growth factor receptor 2 antibody-conjugated quantum dot. Korean J Radiol (2012) 0.77
Radionuclide therapy using (131)I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression. J Cancer Res Clin Oncol (2015) 0.76
Radioactive Nanomaterials for Multimodality Imaging. Tomography (2016) 0.75
The Role of Molecular Imaging in Drug Delivery. Drug Deliv (Lond) (2015) 0.75
Challenges in endocrinology: moving from the post-genomic era, into the nano-world and beyond. Front Endocrinol (Lausanne) (2011) 0.75
Targeting orthotopic gliomas with renal-clearable luminescent gold nanoparticles. Nano Res (2017) 0.75
Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. Amino Acids (2017) 0.75
Quantum dots for live cells, in vivo imaging, and diagnostics. Science (2005) 21.62
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Semiconductor nanocrystals as fluorescent biological labels. Science (1998) 16.68
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science (1998) 14.44
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev (2003) 11.29
Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 7.79
Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science (2003) 7.33
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science (2003) 6.92
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
Molecular imaging. Radiology (2001) 5.67
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A (2002) 5.35
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun (2005) 4.06
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug Chem (2007) 2.98
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000) 2.30
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res (2007) 2.19
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
Hydroxylated quantum dots as luminescent probes for in situ hybridization. J Am Chem Soc (2001) 2.12
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst (1987) 1.95
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
Optical coding of mammalian cells using semiconductor quantum dots. Anal Biochem (2004) 1.46
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci (2007) 1.33
Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett (2007) 1.30
DEPRESSION OF PHAGOCYTIC ACTIVITY AND IMMUNE RESPONSE BY METHYL PALMITATE. Am J Physiol (1964) 1.13
Semiconductor quantum dots for in vivo imaging. J Nanosci Nanotechnol (2007) 1.07
Efficient, stable, small, and water-soluble doped ZnSe nanocrystal emitters as non-cadmium biomedical labels. Nano Lett (2007) 1.03
Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Pathol (1980) 1.00
Combined tyramide signal amplification and quantum dots for sensitive and photostable immunofluorescence detection. J Histochem Cytochem (2003) 0.99
Mortalin imaging in normal and cancer cells with quantum dot immuno-conjugates. Cell Res (2003) 0.93
Towards multi-colour strategies for the detection of oligonucleotide hybridization using quantum dots as energy donors in fluorescence resonance energy transfer (FRET). Anal Chim Acta (2006) 0.90
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
The genome of the mesopolyploid crop species Brassica rapa. Nat Genet (2011) 8.23
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
Nova regulates brain-specific splicing to shape the synapse. Nat Genet (2005) 6.58
Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res (2006) 6.45
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol (2007) 5.53
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
Unusual intron conservation near tissue-regulated exons found by splicing microarrays. PLoS Comput Biol (2006) 4.63
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Genetic and genomic analysis of a fat mass trait with complex inheritance reveals marked sex specificity. PLoS Genet (2006) 3.51
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci (2010) 3.41
Human genomic deletions mediated by recombination between Alu elements. Am J Hum Genet (2006) 3.15
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
Genome-wide RNAi screen reveals a specific sensitivity of IRES-containing RNA viruses to host translation inhibition. Genes Dev (2005) 2.83
A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med (2004) 2.81
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
Heritability of alternative splicing in the human genome. Genome Res (2007) 2.76
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother (2012) 2.65
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell (2012) 2.54
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
A Drosophila resource of transgenic RNAi lines for neurogenetics. Genetics (2009) 2.45
Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res (2008) 2.44
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol (2006) 2.33
Agricultural origins and the isotopic identity of domestication in northern China. Proc Natl Acad Sci U S A (2009) 2.32
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother (2011) 2.30
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
Aberrant light directly impairs mood and learning through melanopsin-expressing neurons. Nature (2012) 2.26
The Drosophila melanogaster transcriptome by paired-end RNA sequencing. Genome Res (2010) 2.25
Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One (2009) 2.21
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Gaussian Bare-Bones Differential Evolution. IEEE Trans Cybern (2013) 2.08
Identification of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data. Circ Res (2007) 2.07
Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res (2004) 2.07
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis (2010) 2.02
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry (2006) 1.96
Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet (2012) 1.96
COPI activity coupled with fatty acid biosynthesis is required for viral replication. PLoS Pathog (2006) 1.95
Selective anesthesia-induced neuroinflammation in developing mouse brain and cognitive impairment. Anesthesiology (2013) 1.93
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem (2004) 1.93
Molecular evidence for spread of two major methicillin-resistant Staphylococcus aureus clones with a unique geographic distribution in Chinese hospitals. Antimicrob Agents Chemother (2008) 1.91
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat (2009) 1.90
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc (2008) 1.89
ANOSVA: a statistical method for detecting splice variation from expression data. Bioinformatics (2005) 1.88
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A (2003) 1.87
Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis (2008) 1.87
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J (2005) 1.85
MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets (2005) 1.83
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther (2006) 1.81
High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med (2011) 1.80
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A (2007) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Unusual magnetic properties of one-dimensional molecule-based magnets associated with a structural phase transition. Inorg Chem (2002) 1.78
Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. Ann Neurol (2012) 1.76
Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol (2008) 1.75
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol (2003) 1.73
Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets (2004) 1.72
Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging (2011) 1.70
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68
Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev (2014) 1.68
MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J (2012) 1.67
Emergence of primate genes by retrotransposon-mediated sequence transduction. Proc Natl Acad Sci U S A (2006) 1.66
Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem (2007) 1.64
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64